UNSPSC 51171930: Candoxatril or candoxatrilat

This classification denotes an antihypertensive agent with the molecular formula C29H41NO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ACP75508EE, chemically known as (.alpha.s)-1-((cis-4-carboxycyclohexyl)carbamoyl)-.alpha.-((2-methoxyethoxy)methyl)cyclopentanepropionic acid, .alpha.-5-indanyl ester, but generally known as candoxatril, which bears US NIH Compound Identifier 5362417. European Medicines Agency schedules candoxatril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06072MIG.

Candoxatril or candoxatrilat bears US NLM identifiers UMLS ID C0077780 and NCI Concept Code C77602. SMILES: COCCOCC(CC1(CCCC1)C(=O)NC2CCC(CC2)C(=O)O)C(=O)OC3=CC4=C(CCC4)C=C3.

UNSPSC 51171930 Candoxatril or candoxatrilat is a Commodity code with minimal relevance to recent state and local procurement activity. The code nominally describes a specific pharmaceutical active ingredient used in cardiovascular therapies, but recent state and local solicitations tagged under it do not procure candoxatril or candoxatrilat products. Instead, the opportunities reflect broader pharmaceutical and drug-testing services procurement: Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services (due July 23, 2026, with an estimated contract value of $600,000 over two years), the Texas Health and Human Services Commission posted an RFI on direct-to-manufacturer prescription programs to gather vendor capabilities, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicited generic multi-source pharmaceuticals and OTC products from manufacturers (due March 26, 2026). The code shows no alignment between its narrow commodity definition and the actual procurement scope—the opportunities involve drug-testing operations, pharmacy benefit program administration, and generic pharmaceutical distribution rather than procurement of candoxatril or candoxatrilat as an active ingredient or finished pharmaceutical product.

Recent activity spans Texas and Minnesota, with Texas Health and Human Services and the Minnesota Department of Administration's Office of State Procurement as primary buyers. The Collin County RFP for drug testing reflects criminal justice and corrections-focused demand, requiring SAMHSA, Texas DPS, or CAP lab certification and covering immunoassay screening with confirmation testing across approximately 25,031 annual tests, with pricing submitted per-test and evaluation weighted toward vendor understanding (30 points), firm qualifications (25 points), client references (15 points), and cost (30 points). The MMCAP pharmaceutical RFP covers a two-year cooperative purchasing term with optional extensions, mandatory relationships with authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), and pricing weighted 75 percent toward price competitiveness with administrative fees of 3 percent. The mismatch between the code's narrow pharmaceutical-ingredient scope and these broad drug-testing and generic-pharmaceutical opportunities indicates the code carries limited procurement signal for firms targeting state and local government contracts for candoxatril or candoxatrilat specifically.